Search results
Results From The WOW.Com Content Network
Title. CEO, Sanofi. Term. September 2019-. Predecessor. Olivier Brandicourt. Children. 3. Paul Hudson (born 14 October 1967) [2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Born. ( 1956-02-13) 13 February 1956 (age 68) Casablanca, Morocco. Nationality (legal) French. Occupation. Business executive. Olivier Brandicourt (born 13 February 1956) is a French business executive and physician, and the former chief executive officer of Sanofi .
Gen Xers and baby boomers taking "too long" to adapt to the new retirement system, Goldman Sachs says.
It seems that months of contentious merger talks between French pharmaceutical company Sanofi-Aventis (SNY) and U.S. biotech Genzyme (GENZ) have entered the home stretch. Sanofi is expected to ...
Last week, Hudson proudly announced his company’s new partnership with OpenAI and Formation Bio, a biotech. In the first-of-its-kind partnership, Sanofi will give OpenAI access to its databases ...
Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur. 2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi ...
Biotech company Dendreon (NAS: DNDN) and French pharma giant Sanofi (NYS: SNY) announced layoffs earlier this week. What do these staff reductions signify for the companies and investors? Let's ...